Nintedanib the game changer in COVID 19 patients

Effect of nintedanib in the prognosis of young and middle aged COVID 19 patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/035256

Enrollment

100

Registered

2021-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Nintedanib drug trial: Nintedanib is given to COVID 19 patients and assess the prognosis and over all survival Intervention2: Not applicable: Not applicable Intervention3: Nintedanib: 1

Eligibility

Inclusion criteria

Inclusion criteria: Without any comorbidities

Exclusion criteria

Exclusion criteria: Diabetes, hypertension, IHD, CKD, immunosuppressive status, old age

Design outcomes

Primary

Measure	Time frame
We are collecting the samples by taking into consideration of rtpcr positivity in covid patients and we will assess the inhospital mortality and prognosis of patients during there hospital stayTimepoint: 4 to 6 weeks	—

Secondary

Measure	Time frame
To asses the prognosis in COVID 19 patients who had taken the drugTimepoint: 10th day from the day of administration of the drug	—

Countries

India

Contacts

Public ContactArunkumar u

Subbiah institute of medical science and research center

arunkumar1070@gmail.com9741914041

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026